EGFR Mutation Testing in Patients with Advanced Non-Small Cell Lung Cancer: A Comprehensive Evaluation of Real-World Practice in an East Asian Tertiary Hospital

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Choi, Yoon La ^a,b   Sun, Jong Mu ^a   Cho, Juhee ^b,c   Rampal, Sanjay ^c,d,e   Han, Joungho ^a   Parasuraman, Bhash ^f   Guallar, Eliseo ^c,d   Lee, Genehee ^a   Lee, Jeeyun ^a   Shim, Young Mog ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e UNIVERSITY OF MALAYA   (Malaysia)

^f ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FEMALE; GENE DELETION; GENE FUNCTION; GENE MUTATION; GENETIC SCREENING; HISTOPATHOLOGY; HUMAN; KOREA; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MISSENSE MUTATION; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; ONCOGENE; OUTCOME ASSESSMENT; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; TERTIARY HEALTH CARE;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PREVALENCE; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; TERTIARY CARE CENTERS;

EID: 84874544125     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056011     Document Type: Article

References (19)

1. Inoue A, Suzuki T, Fukuhara T, Maemondo M, Kimura Y, et al. (2006) Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 24: 3340-3346.
2. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957.
3. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, et al. (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361: 958-967.
4. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, et al. (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380-2388.
5. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, et al. (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11: 121-128.
6. Sharma SV, Bell DW, Settleman J, Haber DA, (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7: 169-181.
7. Keedy VL, Temin S, Somerfield MR, Beasley MB, Johnson DH, et al. (2011) American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 29: 2121-2127.
8. National Comprehensive Cancer Network (2011) NCCN Clinical Practice Guidelines in Oncology: Non-small Cell Lung Cancer, Version 1. Available: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed 2012 Sep 28.
9. Salto-Tellez M, Tsao MS, Shih JY, Thongprasert S, Lu S, et al. (2011) Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approach. J Thorac Oncol 6: 1663-1669.
10. Lynch JA, Lathan CS, (2011) Disparities in access to the EGFR assay. Cancer Epidemiol Biomarkers Prev 20 (10 Suppl): B79.
11. Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, et al. (2005) EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23: 857-865.
12. Tanaka K, Hata A, Kida Y, Kaji R, Fujita S, et al. (2012) Gefitinib for a poor performance status patient with squamous cell carcinoma of the lung harboring EGFR mutation. Intern Med 51: 659-661.
13. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, et al. (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448: 561-566.
14. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, et al. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 1693-1703.
15. Sun PL, Seol H, Lee HJ, Yoo SB, Kim H, et al. (2012) High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features. J Thorac Oncol 7: 323-330.
16. Dacic S, (2008) EGFR assays in lung cancer. Adv Anat Pathol 15: 241-247.
17. Gupta R, Dastane AM, Forozan F, Riley-Portuguez A, Chung F, et al. (2009) Evaluation of EGFR abnormalities in patients with pulmonary adenocarcinoma: the need to test neoplasms with more than one method. Mod Pathol 22: 128-133.
18. Leary AF, Castro DG, Nicholson AG, Ashley S, Wotherspoon A, et al. (2012) Establishing an EGFR mutation screening service for non-small cell lung cancer- sample quality criteria and candidate histological predictors. Eur J Cancer 48: 61-67.
19. Gately K, O'Flaherty J, Cappuzzo F, Pirker R, Kerr K, et al. (2012) The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC. J Clin Pathol 65: 1-7.